What actually changes your next step

Two osteoarthritis decisions often get muddled together in clinic notes and scan reports: what a knee MRI bone marrow lesion actually changes, and when a hip injection genuinely enters the conversation. In practice, they sit at different points on the pathway. A knee bone marrow lesion is an MRI finding that may help explain pain and may signal a joint environment linked with progression, but it is not a stand-alone diagnosis and does not, by itself, create a separate treatment track. Similar lesions can also appear outside a single osteoarthritis pattern, so the finding only becomes useful when it fits the symptoms, examination and the rest of the imaging picture.

The hip question is usually less about a scan label and more about whether day-to-day function is still poor after core care has been tried. Education, exercise, weight loss where relevant and suitable NSAIDs remain the base of treatment; a corticosteroid injection is mainly a short-term symptom option, with benefit often described in weeks rather than durable change. That discussion is usually selective rather than automatic, especially because guideline positions on hip injections are not fully aligned.

Do knee bone marrow lesions matter

On a knee MRI, a bone marrow lesion usually means a change in the bone just under the joint surface — the subchondral bone — rather than a random blur on the scan. Reviews of knee osteoarthritis describe these lesions as biomarkers of OA-related subchondral bone change, often seen alongside other joint pathology such as cartilage damage. The practical point is simple: the term sounds technical, but it is not usually meaningless scan jargon.

Why clinicians pay attention to it is less about the label itself and more about what it may represent. A 2022 review linked osteoarthritis-related bone marrow lesions with both pain and structural worsening over time. Tissue studies from arthritic knees also show that areas matching these MRI lesions can contain more blood vessels, scar-like fibrous change, inflammatory cells and thickened bone struts, with extra nerve growth around vessels in some samples. That does not prove that every lesion is the source of pain, but it does make the symptom link biologically plausible.

The caution is that a bone marrow lesion is not unique to osteoarthritis. Differential diagnosis matters, so the MRI finding is a clue, not a verdict, and a painful knee is not always explained by one scan feature alone.

When a knee MRI should change treatment

The point at which a knee MRI most changes management is usually after the standard plan has stalled. In the 2020 JAMA review, the base of osteoarthritis care remained education, exercise, weight management where relevant, and analgesia or NSAIDs in suitable patients. If pain is still limiting walking, stairs or daily loading after that, an MRI finding such as a bone marrow lesion is usually best treated as part of a reassessment rather than as a stand-alone diagnosis.

One practical takeaway stands out: MRI may sharpen decisions about load modification, symptom monitoring and how confidently the scan findings fit the rest of the clinical picture; it does not, on current evidence, unlock a proven lesion-specific fix for routine knee osteoarthritis care.

That is why the MRI finding often changes the emphasis from "keep pushing through" to "reassess load and function", rather than pointing to a single protocol. In practice, treatment is usually individualised: core care first, then a review of mechanics, symptoms and the broader joint picture. What remains uncertain in the current knee literature is how far targeting the lesion itself changes the long-term course of osteoarthritis.

When a hip injection is worth discussing

Rather than repeating the full non-surgical ladder, the practical threshold is narrower: a hip injection becomes worth discussing when the basics have had a fair run and pain is still running the day. In the 2020 JAMA review and the 2019 OARSI guidance, the foundation remained education, structured exercise, weight loss where relevant, and NSAIDs when they are appropriate and safe. If, after that, hip pain is still limiting everyday activities or stopping rehab from progressing, an injection discussion becomes reasonable.

The clearest case is for an intra-articular corticosteroid injection as short-term symptom relief, not as a way to reverse hip osteoarthritis. Review-level evidence suggests pain and function can improve for weeks, sometimes up to about 12 weeks. In practice, that limited window may still matter when a flare has made daily function difficult or when temporary relief could help someone continue exercise-based care rather than abandon it.

The important caveat is that guidance is not fully aligned. The 2019 OARSI guideline did not recommend routine intra-articular corticosteroids for hip OA, even though review-level evidence supports short-term benefit. That leaves hip injection in a selective rather than automatic role: sometimes useful for symptom control, but not established as disease-modifying treatment or a reliable way to avoid replacement.

How timing changes the hip injection decision

Set the broader injection debate aside: once total hip replacement looks plausible in the near term, the main question becomes whether a short-term injection would actually change the pathway or simply add another temporary step. The strongest support in the attached sources is for corticosteroid injection as short-term symptom relief, not as a treatment that reverses hip osteoarthritis. That makes timing relevant in a practical sense: if surgery is already coming into view, the value of a temporary measure has to be weighed against the overall plan.

The evidence base for hip injections is also narrower than it can sound in routine conversation. Review and guideline sources describe limited randomised evidence for hip corticosteroid injections, and guideline support is mixed rather than universal. Taken together, that supports a cautious message: when arthroplasty may be the next stage, injection decisions are usually framed around symptom control and pathway planning, not around disease modification.

That same near-surgery logic makes less-established injections harder to justify as standard care. OARSI 2019 did not recommend hyaluronic acid for hip OA, and the attached sources do not place newer injectable options into established routine care for this setting.

1. [1] Diagnosis and treatment of hip and knee osteoarthritis: A review. (2021). https://doi.org/10.1001/jama.2020.22171 https://doi.org/10.1001/jama.2020.22171